Improved Bladder Cancer Therapy With Recombinant BCG

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$253,882.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA130235-01
Agency Tracking Number:
CA130235
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
BACILLIGEN, INC.
BACILLIGEN, INC., 9700 GREAT SENECA HIGHWAY, ROCKVILLE, MD, 20850
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
780463472
Principal Investigator:
DAVID HONE
(301) 217-9525
DHONE@BACILLIGEN.COM
Business Contact:
STEVEN BENDE
() -
sbende@bacilligen.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The long-term goal of this product development plan is to develop a recombinant bacille Calmette-Gu rin (rBCG) strain that displays reduced toxicity and improved cancer immunotherapeutic properties. We believe that we can achieve this goal by altering both the tissue-binding and proinflammatory properties of BCG. The central hypothesis of this project is that genetic manipulation of BCG to enhance factors associated with antitumor activity will improve the safety and po tency of this biologic. To address this hypothesis we propose to complete the studies in the following specific aims: Specific Aim 1 :- Construction of rBCG that constitutively expresses a tissue adherence factor - The objective of this aim is to produce a n rBCG that constitutively over-expresses fibronectin attachment protein, FapB. This protein and the attachment to fibronectin were shown to be necessary for BCG-mediated protection against bladder cancer in animal models. Strains that carry a recombinant constitutive FapB expression cassette will be verified genotypically and phenotypically. Specific Aim 2 :- Construction of rBCG with altered immunostimulatory properties - The objective of this aim is to produce rBCG strains that express the RD1 region, wh ich has been shown to increase the immunostimulatory properties of BCG, and a pro-apoptosis factor, which we predict will increase antitumor activity and ameliorate the reactogenicity of BCG. BCG strains expressing RD1, a pro- apoptosis factor, or both wil l be validated genotypically and phenotypically. This project will be milestone-driven and at the conclusion of each milestone the Senior Executive Team (SET) will review the results and recommend one of the following decisions: Go: proceed to the next sta ge; Redirect: based on incomplete deliverables, changed objectives or strategy; No-go: terminate the project. In addition to the milestone review, the SET will also review plans for continuation activities. Overall, we believe that these studies will resul t in the development of an improved bladder cancer therapeutic and contribute to our understanding of the BCG-host interaction in the development of protection against bladder cancer.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government